Please login to the form below
cost
This page shows the latest cost news and features for those working in and with pharma, biotech and healthcare.
Shionogi scores FDA approval for new cUTI antibiotic
The development of new drugs to treat antibiotic resistant germs is well overdue, as pharma companies have halted research in this area as there is no significant payback for the cost
Latest news
-
MSD hangs ‘for sale’ sign on French facility, shedding 207 staff
Job losses will be across manufacturing and R&D divisions. Merck &Co/MSD has set another part of its ongoing cost-cutting drive in motion, announcing the closure of a plant ... The company said in May that it plans to close a number of plants and reduce
-
FDA advisors say no to empagliflozin in type 1 diabetes
That means Boehringer and Lilly now have to decide whether approval in type 1 diabetes is worth the cost of running another trial.
-
The end of pharma
In both cases, it is difficult to see how to adapt to the market’s dominant selection pressure, which favours lower costs and therefore commoditisation.
-
Election 2019: Labour tops Tory pledge on NHS spending
Health Secretary Matt Hancock said: “Jeremy Corbyn's plans for a four-day working week will cripple our economy and cost the NHS billions every year.
-
NICE backs first cannabis-based drugs, both from GW Pharma
Updated guidelines from cost-effectiveness watchdog NICE back the use of GW Pharma’s Epidyolex (cannabidiol) for the treatment of seizures in patients with Lennox Gastaut syndrome (LGS) or Dravet syndrome –
More from news
Approximately 9 fully matching, plus 2,807 partially matching documents found.
Latest Intelligence
-
Strengthening business competition and reducing anti-competitive practices
Cost: both in terms of reduced fines (settling companies can and commonly do achieve a maximum discount on potential penalty of 20%) and saving/better utilising resources (settling with the CMA ... means committing to a streamlined administrative process
-
The long and winding road to asthma breakthroughs
Severe eosinophilic asthma (SEA) impacts between 5-10% of the population but they, and other severe asthma subtypes, represent 50% of the cost of asthma care expenditure.
-
Delivering the promise of regenerative medicine
but only for a limited time period. By streamlining the currently very expensive manufacturing process and improving supply chain management, yields will automatically get larger and costs will slowly come down.
-
Assessing the risks in annuity pricing models
Input from industry insiders and experts identified a range of concerns associated with annuity payment models, including a potentially significant impact on cost of capital and company valuations, costs and burden ... The financial impact of annuity
-
Creating value from value-based healthcare
An opportunity or a threat for pharma? On the surface, VBHC appears to be an opportunity predominantly for policymakers to achieve better health outcomes at a lower cost. ... The companies that are able to identify the systems and stakeholders willing to
More from intelligence
Approximately 1 fully matching, plus 460 partially matching documents found.
Latest appointments
-
Merck appoints new chief information officer
He has a proven track record in successfully managing large-scale IT transformation initiatives, as well as building cost-effective international IT organisations.”.
-
Peter Kelly named managing director of Accord Healthcare UK
We remain committed to R&D and bringing cost competitive new products to market at the earliest opportunity.
-
IFPMA appoints Fumie Griego as assistant director general
and background in global affairs, including intellectual property protection, pricing, costs, value issues and health diplomacy.
-
Sandoz UK promotes Tim de Gavre to country head
As a market, the UK has one of the highest levels of generic use of any global market, and the NHS is also under severe cost pressures. ... Our combined portfolio of small molecule generics and biosimilars makes a significant different to medicines costs,
-
EY appoints global life sciences industry leader
New solutions will be required to meet the global challenges of sustainability of healthcare systems, aging populations, chronic disease and increasing cost pressures.
More from appointments
Approximately 0 fully matching, plus 19 partially matching documents found.
Latest from PMHub
-
Antibiotic resistance: The silent pandemic
1]. The short-term results are longer hospital stays, the requirement of second- and third-line antibiotics resulting in higher medical costs, and increased mortality [1, 2].
-
New opportunities in emerging markets
aggressive cost containment measures).
-
Valid Insight: TRAVELLESS, the Virtual Workshop Solution for Pharma
Valid Insight’s virtual workshops can provide a cost-and-time effective solution, eliminating the challenges above, without any IT and technology concerns.
-
Havas Lynx Launches Specialist Clinical Trial Recruitment Agency, Havas Lynx Faze
cost of finding patients.
-
Stephen Fry voices new Aardman animation on the shocking state of mental health worldwide
Suicide is the second leading cause of death among 15-29 year-olds worldwide, and mental ill health currently costs the world 2.5 trillion dollars per year.
More from PMHub
Approximately 3 fully matching, plus 348 partially matching documents found.
Featured jobs
-
Account Executive
-
Salary TBC
-
Account Supervisor
-
Salary TBC
- Graduate / Entry Level Opportunities – Medical Communications – ...
-
Highly Competitive Remuneration Package
- Senior Medical Writer – Leading Medical Communications Agency – ...
-
Highly Competitive Remuneration Package
- Account Manager / Senior Account Manager - Creative MedComms - C...
-
Excellent Remuneration
- Entry Level Editorial Assistant – Medical Education –Buckinghams...
-
Highly Competitive
-
Account Director, Medical Education
-
Salary TBC
- Senior / Principal Medical Writer – Medical Education - UK &...
-
Excellent Salary and Benefits on offer
- Senior Medical Writer– Medical Education – Oxford - London
-
Excellent Remuneration Package
- Account Director, Healthcare Communications Agency
-
£54, 000- £60, 000
- Scientific Director - Medical Communications Agency - New York
-
Excellent Remuneration Package
- Account Manager, Healthcare Communications
-
£32, 000 - £40, 000 bonus benefits
- Senior Editor - Medical Communications - South East - Buckingham...
-
Highly competitive salary &package
-
Senior Medical Writer
-
Salary TBC
- Scientific Director - Medical Education - Cheshire & London ...
-
Excellent Remuneration Package
-
Account Director
-
Salary TBC
- Scientific Director - Medical Communications - Berkshire
-
Excellent package on offer
- Experienced / Senior Medical Writer - MedComms - Cardiff - Wales
-
Excellent Salary and Benefits on offer
Subscribe to our email news alerts
- Takeda highlights 12 NMEs with $10bn-plus sales potential at R&D day
- MSD hangs ‘for sale’ sign on French facility, shedding 207 staff
- Nucala works in rare inflammatory disease, says GSK
- MSD hangs ‘for sale’ sign on French facility, shedding 207 staff
- Otsuka presses on with Alzheimer’s agitation drug
- Four Ms
- Using human insights to push healthcare communications forward
- RWE Blog 4: The place of real-world evidence in the market access strategy
- Don’t we all need to be able to change something?
- Antibiotic resistance: The silent pandemic
- BMS, Celgene merger should close this week after FTC okay
- The NHS is facing shortages of lifesaving treatments, says internal document
PMHub
Novasecta
We are a specialist strategy consulting firm for pharmaceutical and biotech companies. We help our clients to achieve significant performance...
Latest intelligence
- Using human insights to push healthcare communications forward
- This blog highlights the value of human perspectives, showing how insights can propel healthcare communications forward to ultimately improve lives...
- RWE Blog 4: The place of real-world evidence in the market access strategy
- The fourth and final blog in our latest series focuses on market access strategy. This follows our evaluation of the role of real-world data (RWD) and real-world evidence (RWE) in...
- RWE Blog 3: Is real-world evidence the holy grail
- We began our four-blog series by evaluating the role of real-world data (RWD) and real-world-evidence (RWE) in Real-world challenges and real-world data, and understanding the payer's perspective, in Payers use...
Quick links
Infographics
